Topics for Future Posts

Mammon at the Silicon Investor stock chat board for Provectus raised severals topics for discussion. I'm going to try to blog my thoughts on these topics:

• What are the pros and cons of doing a pivotal MM phase III trial with or without a partner?
• What a potential dermatology deal might look like?
• How does Provectus compare to other biotechnology companies that have recently been bought out?
• Is there a chance for accelerated approval given Moffitt's immunology-related work?
• How do the psoriasis Phase 2c results compare to other gels (not systemic treatments)?
• How might PV-10 work as a first-line treatment?
• What is big pharma's perception of Provectus?
• When does Provectus' share price start representing its true (or intrinsic) value?